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Executive Summary  
Stimuli responsive drug release vehicles have become of increased interest in recent 
years. Common stimuli that have been investigated include light, pH, and temperature. The 
goal of this project was to investigate the drug release profiles of alginate beads that have 
PNIPAAm, a thermal responsive polymer, incorporated into the matrix. The purpose of doing 
this was to create a drug delivery system that can be tuned to have a specific release profile or 
specific release time by varying the amount of PNIPAAm in the delivery matrix. The drug used 
for delivery was rhodamine B. 
 The project was designed to investigate the release speed and mechanism of beads 
made with differing ratios of alginate to PNIPAAm. After obtaining data, the percent of drug 
released versus time can be fitted to a power law curve. This power law curve and its 
corresponding constant and exponent can be classified using a simplified form of Fick’s 2nd Law 
of Diffusion. The constant k describes the speed of the diffusion and is a function of bead 
thickness, while the exponent n describes the diffusion case, which has four distinct regions: 
zero-order constant diffusion, anomalous, Fickian, and pseudo-Fickian.  
 After analysis, it was determined that the mixed PNIPAAm beads had significantly higher 
k values than the pure alginate beads. This shows that the PNIPAAm speeds the drug release. 
This is due to the hydrophobic  behavior displayed by PNIPAAm above its lower critical solution 
temperature (LCST), which causes the pores of the network to collapse and expel the drug. The 
n values for the different systems showed that the release changes from a zero order release 
for pure alginate to a Fickian diffusion case for the 50/50 mixture of alginate and PNIPAAm.  
 One of the largest impacts of my work was on my personal and career goals. In the fall, I 
will be attending the University of Michigan to begin my PhD in Chemical Engineering. I plan to 
pursue a career in academia upon completion of my doctorate. Completing this project has 
increased my confidence in my ability to conduct, analyze, and report original research. I have 
also gained experience in using literature surveys to trouble shoot, explain results, and provide 
supporting evidence. I also had the opportunity to refine my technical skills through using 
laboratory equipment, practicing safe laboratory procedures, and learning to use specific 
equipment, such as the microscope and the plate reader. 
 This project will contribute to the body of work being done by researchers around the 
world to create stimuli responsive drug delivery systems to overcome obstacles and improve 
the efficiency  of release systems. One application of using thermal responsive drug delivery 
systems can lead to advances in topical delivery systems that respond to the body’s 
temperature change, creating a consistent release profile. This could lead to a reduction in 
required dosages. This would increase patient compliance to the recommended treatment 
procedures, which could improve his or her quality of life.  
 The next step for this project would be to confirm the result by obtaining additional data 
sets at the same experimental conditions. If concise results are obtained that show an 
appreciable difference between the n and k values for each ratio of PNIPAAm to Alginate, then 
it would be recommended to continue investigation into tuning the release profile by varying 
the overall % of polymer in the beads. Also, it would be beneficial to test the release profile in 
PBS to give an initial confirmation of the viability of using these beads in vivo. The biggest 
improvements that are needed for success in this project are consistent morphology and an 
improved sampling procedure that ensures the samples obtained are not only of the localized 
concentration. 
 As an undergraduate, I have had the opportunity to explore three different research 
projects. Through these experiences, I would advise other students to choose their advisor 
carefully. An advisor that is highly supportive, easily accessible, and sufficiently able to answer 
questions makes beginning researcher less daunting and more enjoyable. Choose a project that 
excites you, because you are quickly  going to become an expert in your project topic! When 
your hard work returns faulty or meaningless results, and you start to get discouraged, remind 
yourself that failure is a key portion of the research process, and often more is learned through 
failure than success.  I wish students the best as they embark on these endeavors! 
Introduction 
Controlled and targeted drug release has become a topic of great interest among the 
academic and medical community. Conventional drug release systems can be inadequate and 
ineffective for special circumstances. For example, research in administering drugs orally that 
are normally injected necessitates the design of a “smart” release vehicle.
[1]
 Insulin, a protein 
based drug that is typically administered to diabetic patients through a pump or an injection, is 
one such drug. Oral delivery would be preferred to injection to increase patient compliance and 
comfort,
[1] 
but bypassing the stomach and releasing in the intestines for uptake into the blood 
stream can prove to be a difficult task. During the digestive process, proteins are broken down 
into their constituents in the highly acidic stomach environment, which would prove fatal for 
the needed insulin proteins. This type of delivery quandary would warrant the use of a “smart” 
release system that can be activated by environmental stimuli, such as the pH change between 
the stomach and the intestines.  
Another medical opportunity that can be addressed with smart polymers is topical 
applications of drugs. Obtaining the correct distribution of medication in a topical application 
can be particularly challenging if the drug seeps through the skin into the blood stream.
2
 The 
negative outcomes of this scenario can range in severity. In the best case, the quickly leaching 
drug would necessitate frequent applications of the medication, decreasing effectiveness of the 
treatment. More severe cases would include local toxicity in the blood because of the leached 
drug. To approach this issue, research has been done into infusing  electrospun PVA mats with 
PNIPAAm, a thermal responsive polymer, to allow for the topical applicator to respond to the 
temperature change on the body surface.
2
 The study found this to prolong the release and 
promote even distribution of the drug in the affected area while decreasing leaching. Advances 
in using “smart” materials for topical applications will increase treatment effectiveness and 
promote patient compliance. 
Hydrogels are excellent candidates for environmentally sensitive releases because they 
have properties that allow them to achieve rapid transition between swelling and shrinking or 
gel and solid, depending on the type of polymer used.
[3]
 The transition can be initiated by 
relatively small changes in physical or chemical stimuli. Some of the common stimuli that are 
investigated for use in drug delivery include temperature, electric field, light, and pH. The 
following report will introduce investigations into temperature stimulated drug delivery. 
The purpose of this project was to design and test experimental methods to determine 
the impact that incorporating a thermal responsive polymer, PNIPAAm, into alginate beads 
would have on the release of a small molecule model drug, rhodamine B. It was hypothesized 
that the release profile, which is evaluated by fitting the time versus total drug released (up to 
60%)
[4] 
to a Fickian model, can be tuned by varying the ratio of alginate to PNIPAAm in the drug 
delivery matrix. Release behavior was recorded using a modified Franz diffusion cell setup.   
This investigation into incorporating thermal responsive materials into bead carriers for 
targeted drug release is part of a larger investigation into controlled drug release for wound 
healing applications. Work has been conducted on polyelectrolyte beads, which produce pH 
responsive behavior. Better bead synthesis methods are also being developed under this 
project heading to improve the consistency and customizability of bead size and morphology.  
During this project, many recommendations for further investigation were created. Future 
studies should focus on varying the overall weight percent of polymer, as well as evaluating the 
efficiency of the release profile for wet beads at 37 °C and the release profile of wet and dry 
beads at room temperature. The beads should also be released into PBS. A better drug loading 
determination method should be investigated, preferably one that degrades the polymer 
matrices, allowing for complete release of incorporated rhodamine B.   
 
Background 
To exploit the temperature responsive nature of hydrogels as drug delivery vehicles, 
poly(N-isopropylacrylamide) (PNIPAAm) is a commonly used polymer.
[5] 
The structure of 
PNIPAAm is shown in Figure 1. Synthesized via free radical polymerization from N-
isopropylacrylamide (NIPAAm) monomer, PNIPAAm 
exhibits swelling-shrinking response when heated above 
its lower critical solution temperature (LCST), which 
occurs at 32 °C.
[6]
 Since this is close to body temperature 
(37 ⁰C), PNIPAAm is used in many biomedical 
investigations. PNIPAAm can be easily dissolved into an aqueous solution at temperatures 
below the LCST. If a crosslinking agent is added, PNIPAAM can exist as a loose, transparent gel 
at room temperature that becomes hard and opaque when the LCST is exceeded (Figure 2). This 
transitioning behavior is due to the unique constituents of the PNIPAAM molecule, which 
consist of both hydrophilic and hydrophobic components. When the temperature is lower, the 
hydrogen bonds in the side-chain amide group interact strongly with the surrounding water 
molecules. As the temperature is increased, the hydrophobic segments increase intramolecular 
interactions between the polymer chain and other polymer chains. The increase in temperature 
also weakens the hydrogen bonding between the water and the polymer chains.
[3]
 These two 
phenomena cause the network to tighten, expel any interspersed water molecules, and 
decrease in volume. The collapsed network can be observed by a visual change from 
transparent to opaque (See Figure 2). The transition is considered completely reversible and 
almost instantaneous when the material temperature crosses the 32 °C LCST.  
 
One of the downsides of using PNIPAAm in drug release systems is that it is not 
biodegradable.
[5] 
Although it is not biodegradable, a cursory study done by Malonne, Eeckman, 
and Fontaine et al. showed that PNIPAAm and its common copolymers do not appear to cause 
acute or subacute toxicity in mice. The research group asserted that further toxicity studies 
should be conducted prior to approving PNIPAAm for use in human drug delivery systems. 
Despite the possibility of negative effects on the body and the lack of biodegradability, 
PNIPAAm is used frequently in biomedical investigations.  
Because of the biodegradability issues, it is beneficial to combine PNIPAAm with a known 
biodegradable matrix, such as alginic acid (alginate). Alginate is a natural polymer extracted 
from brown seaweed.
[8] 
It is commonly used in the medical field because it is non-toxic, 
biocompatible, and biodegradable. One interesting application of alginate in the medical field is 
the creation of molds for orthodontic applications. Aqueous alginate solutions can be easily 
crosslinked by addition to a dilute calcium chloride solution. 
The resulting hydrogel is commonly used in orally delivered 
drugs, and can be combined with other polymers and 
chemicals to create non-gelatinous soft capsules.
[9]
 Based 
off of the work done by Shi, Alves, and Mano, it was 
decided to investigate if controllable drug release profiles could be achieved by incorporating 
temperature responsive PNIPAAm into alginate beads. Expanding off of their original 
investigation, it was determined that a standard 3 wt.% polymer solution would be used and 
that the ratio of alginate to PNIPAAm would be varied to research the feasibility of creating a 
tunable release profile. The chosen ratios of polymer weight percent of alginate to PNIPAAm 
included 90/10, 75/25, 66/33, and 50/50. Pure alginate beads were used as a control for every 
drug release conducted.  
In order to economically research the effectiveness of drug release matrices, a model drug 
is commonly used. Rhodamine B was selected as the model 
drug for this investigation. This small molecule is assumed 
to accurately mimic the release of actual small molecule 
medications. Rhodamine B is fluorescent magenta, which 
allows for facile absorbance readings and convenient visual 
representation of amount released with respect to time. 
For rhodamine B at low concentrations, the Beer-Lambert 
law can be used to model the absorbance as a function of concentration.
[11]
 This relationship 
can be utilized to create a connection between absorbance of a sample and the amount of drug 
released in the solution. This relationship can be used to model the drug release behavior over 
time.   
Drug release from polymeric beads is a well investigated field. These delivery vehicles can 
be comprised of a degradable matrix or a non-degradable matrix. The kinetics and transport 
mechanisms of the release system are unique to the type of matrix. The alginate and PNIPAAm 
delivery system used for this study is considered to be non-degradable during the chosen 
release period of up to 3 days and in the chosen release medium, DI water (pH 5.5). To model 
the unsteady state small molecule drug release behavior of a non-biodegradable system, Fick’s 
2
nd
 Law can be used. To utilize Fick’s 2
nd
 Law of Diffusion for a one-dimensional system (x-
direction shown), the concentration (c) is found with respect to time as shown in Equation 1 
below.  










Upon substitution and approximations, an alternate form of Fick’s 2
nd
 Law can be derived that 
relates released mass at time t (	) to the equilibrium mass (	
). This equation makes use of 







).).[12] The k constant can be used as a metric to understand how fast the drug will 
release in the system. The exponent n can be used to determine the main mechanism for 
diffusion that the system is following. Descriptions of the possible values for n can be found in 
Table 1.  
Equation 2:   


=   
Table 1: Exponential values for modeling systems using Fick’s 2
nd




n <= 1 
Zero  Order diffusion (Constant rate of diffusion after initial 
penetration of drug)
[8] 
1 > n > 0.5 Anomalous diffusion 
0.5 > n Pseudo-Fickian Diffusion 




Materials used for this project included PNIPAAm (Polysciences, Inc- Mn 40,000), 
rhodamine B (Sigma- ≥95% (HPLC)), alginic acid sodium salt from brown algae (Sigma), and 
calcium chloride (EMD Millipore- anhydrous). DI water used was purified in house and has a 
conductivity of < 1 µS/cm. 
Method 
To test the drug release profile, beads were synthesized. To begin, stock solutions of 
aqueous alginate (3 wt. %) and aqueous PNIPAAm (10 wt. %) were created by dissolving the 
respective polymers in DI water. A stock solution of dissolved rhodamine B was also created. 
Because rhodamine B has limited solubility in water (8 mg/ml),
[13]
 it was important to create an 
aqueous solution of rhodamine B prior to introducing it to the viscous alginate solution. This 
step aids in creating a more uniform drug loading in the beads. Rhodamine B was added on top 
of the measured water, and then stirred magnetically to create a 1.4 wt. % solution. These 
solutions were then combined to create a bead stock solution for each of the four desired ratios 
of alginate to PNIPAAm: 90/10, 75/25, 66/33, and 50/50. Each solution contained a total of 2 
wt. % polymer. After the solutions were combined, each beads solution was vortexed for 10 
seconds to ensure uniform mixing before making the beads. A bath of weak CaCl2 (3 wt. %) and 
rhodamine B (1 wt. %) solution was prepared by dissolving 3 g of CaCl2 in 100 g of water. After 
the CaCl2 was dissolved, additional rhodamine B (1 g) was dissolved in the bath. The addition of 
rhodamine B was used to decrease the likelihood of rhodamine B leaching out of the beads 
during preparation.  
Beads were formed by adding the alginate, PNIPAAm, and rhodamine B solution dropwise 
to the CaCl2 bath, which was being magnetically stirred rapidly. The bead solution was added to 
a 3 CC syringe, and then extruded by hand with a consistent pressure at a rate of two drops per 
second through a 20 G surgical needle. The needle was held approximately 2 cm from the 
surface of the liquid.  
After exhausting the solution in the syringe, beads were immediately removed from the 
solution by filtering through a wire mesh. The beads were then rinsed with ~5 mL of DI water to 
remove excess CaCl2. The mesh was set on KimWipes to absorb excess moisture before 
photographing the beads. Bead photographs were taken prior to drying so that the morphology 
could be observed (Figure 7). Beads were then transferred to a fume hood, where they were 
allowed to dry for approximately 1 week. Beads were photographed again post drying (Figure 
8).  
The drug release was done using a modified Franz diffusion 
cell release chamber (Fig. 5 & 6). The chamber consists of a 50 mL 
centrifuge tube with a modified lid that accepts a G14 surgical 
needle. A second hole in the lid minimizes pressure issues during 
sampling. This chamber was created by Dr. Bi-min Newby and Eric 
Brink (The University of Akron, Department of Chemical and Biomolecular Engineering). To 
begin the release, a water bath was prepared at 37 °C using an 
incubator (PolyScience). The incubator was filled with water deep 
enough to submerge the centrifuge tubes up to their 45 mL mark. 
Needle tips were wrapped in cotton gauze to provide a physical 
barrier to prevent uptake of beads during sampling. Beads were 
weighed and recorded, in groups of 5, and then added to the bottom 
of the chamber. Once all chambers were filled with 5 beads, the first 
chamber was filled with DI water to the 45 mL mark, then 
immediately placed in the water bath. To maintain accuracy of timing between sampling 
periods, one chamber was filled per minute. In order to obtain a standard deviation and ensure 
the accuracy of results, each different alginate to PNIPAAm ratio was tested in triplicate and 
tested at the same time as a pure alginate control.  
Once the chambers were filled, samples of the release environment were taken at regular 
intervals. For the first hour, samples were taken every 15 minutes. For the second hour, 
samples were taken every 30 minutes. For the next four hours, the samples were taken every 
hour. Longer time samples were taken to use as the drug loading measurement. For each 
sample, a 1 mL syringe was inserted into the chamber’s port, the syringe was pumped 5 times, 
and approximately 0.5 mL of solution was removed. The solution-filled syringe was set on a 
scale, which was then tared. The solution was emptied into a microcentrifuge tube, then the 
syringe was placed back on the scale and the difference in weight was recorded. To prevent 
contamination between sampling, the sampling syringe was rinsed with DI water between 
samples. To maintain a constant volume release environment, 0.5 mL of DI water was added to 
the chamber with a clean syringe after each sample was taken. 
After completing the sampling cycle, with the final measurement after 120 hours to 
determine drug loading, the samples were analyzed for drug content. Any sample that had a 
rhodamine B concentration higher than 5 ppm was diluted with DI water to maintain the 
accuracy of the Beer-Lambert law calibration.
[11] 
The weight of added water was recorded. For 
accurate readings, the concentration of rhodamine B in aqueous solution also had to remain at 
a level where the absorbance would not exceed 1. For each sample, 200 µL of solution were 
removed from each centrifuge vial and placed in a 96-well plate. The Tecan Infinite M200 Plate 
Reader was used to read the absorbance of each well at a wavelength of 554 nm.
[11]
 These 
absorbance readings, along with the sample weights, dilution weights, and sampling times, 
were used to calculate the amount of drug released at each sample time. The amount released 
at each sample time was converted into a percentage by using the total amount of drug 
released. 
As mentioned previously, rhodamine B can be analyzed via absorbance measurements, 
and at low concentrations (5 ppm or less), can be evaluated using Beer-Lambert law. The Beer-
Lambert law is shown in Equation 3, where A is the absorbance (no units), c is the 




, and b is the path length in 
cm.  
Equation 3:   =   
The Beer-Lambert law is only valid in linear regions, with the εb term representing the 
slope of the line. This constant was previously determined for rhodamine B in water by creating 
a serial dilution of samples, taking absorbance readings at 554 nm wavelength light, then 
performing a linear regression on that data. The value of the calibration curve slope (εb) was 
found to be 0.1338. The concentration of rhodamine B in each sample was obtained via 
Equation 4, which is a rearrangement of Equation 3, using the calibration curve slope for εb.  




The path length, l, was assumed to be constant, and was thus reported analyzed data was 
assumed to be independent of path length. To find the gram amount of drug in each 
representative sample, Equation 5 was used. To determine the gram/gram concentration of 
rhodamine in the representative sample, Equation 6 was used. This g/g concentration was then 
multiplied by the amount of solution in the sampling environment (45 mL) to find the total 
gram amount of rhodamine B in the sampling environment at the time of sampling. These 
values, along with the drug loading, were used to find a percentage release at each sampling 
time 
Equation 5:  67 "# 8 !9:$ =
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 After calculations, the percent drug released was then plotted as a function of time. The 
graph was truncated after 60% drug release. For a polymeric matrix, the simplified version of 
Fick’ law shown in Equation 2 is only applicable up to 60% release from a polymeric matrix.
[4] 
The data was fitted to a power law curve, and the coefficients and exponents were recorded in 
Table 2. Correct safety and waste disposal procedures were followed to dispose of chamber 
liquid and remaining beads.  
Data and Results 
The synthesis of the drug release beads was quantified by taking photographs of the wet 
beads (Figure 7) and dry beads (Figure 8). From these pictures, assessment of the size and 
surface morphology can be made.  
The release behavior of the beads was analyzed using Excel. The percent drug released 
with respect to time was calculated via the method outlined above. The percent drug released 
was graphed versus time, and then fitted to a power law trend line. (Figure 9) The equation for 
the trend line was used to determine the n and k values, as shown in Equation 2. As previously 
mentioned, the constant k represents the speed of diffusion, and the exponent n explains the 
release behavior. Values for k, n, and the assumed release case for each type of bead can be 




Figure 9: Graph of drug released versus time for all 6 types of beads. Error bars are shown to 
show standard error for each data point. Each point is the average of three data readings. The 
trend lines shown were obtained using a power law fit. The dotted red line represents the 60% 
release threshold for modeling diffusion using Equation 2. 
 
Table 2: A summary of the coefficient k and exponent n for each type of bead. The case, based 
off of the exponent n as defined in Table 1, is also listed.  
  k n Case 
Alg Ct1 0.3370 1.07 Constant Rate of Diffusion 
Alg Ct2 0.1488 0.78 
Anomalous / Constant Rate of 
Diffusion 
90/10 0.5728 0.63 Anomalous Diffusion 
75/25 0.6121 0.32 Pseudo-Fickian Diffusion 
66/33 0.4201 0.39 Pseudo-Fickian Diffusion 
50/50 0.4554 0.48 Fickian Diffusion 
 
 
Table 3: Summary of estimated times for 60% release and drug loading for each type of bead. 
  
60% release 
time (h) Std Dev 
Drug Loading 
(mg) Std Dev 
Alg Ct1 2 9.5% 0.2334 3.0% 
Alg Ct2 7 4.2% 0.3498 2.4% 
90/10 1 5.1% 0.1883 3.1% 
75/25 0.9 5.4% 0.1613 1.2% 
66/33 3 5.7% 0.4242 2.2% 
50/50 2 3.6% 0.5188 7.0% 
 
Discussion / Analysis 
An analysis of the efficiency and behavior of a drug release system can be evaluated from 
the n and k constants produced from fitting the experimental data to a Fickian diffusion model. 
Based off of the n and k values, it can be seen that the addition of PNIPAAm to the system can 
significantly alter the release profile. In general, the addition of PNIPAAm speeds the release, as 
seen by the significantly larger k values for the mixed beads as compared to the pure alginate 
beads. This behavior can be attributed to the LCST behavior of PNIPAAm. Since the PNIPAAm is 
fully incorporated into the crosslinked alginate network, the pores of the network will collapse 
when the LCST is reached, promoting the expulsion of the rhodamine D molecules and 
accelerating the drug release. Previous investigations into drug release from PNIPAAM and 
alginate beads has shown similar behavior, with the drug releasing more rapidly when the 
beads were brought above the LCST of the PNIPAAm.
[10]
  
It can also be observed that the addition of PNIPAAm quickly moves the release system 
from exhibiting a constant diffusion profile when no PNIPAAm is added towards exhibiting 
Fickian diffusion for the highest percentage of PNIPAAm (50/50). With increasing polymer 
percentage of PNIPAAm, the release profile starts to behave according to a Fickian model. It 
would be of interest to determine if pure PNIPAAm beads exhibit Fickian diffusion.  
The 60% release threshold for modeling shows the upper end of the range over which the 
Fickian diffusion model holds.
[4] 
There was not a discernable trend to relate the 60% release 
time with the amount of PNIPAAm added, which could be attributed to experimental errors. 
Since both alginate control bead data sets were created using the same batch of beads, the 
significantly variable k values and 60% release times may be due to environmental variation 
between the two release recordings. One such investigation variable could be non-uniform 
temperature in the incubator. The release environment was kept open for the duration of 
sampling, which could allow for non-uniform change in heat in the water bath.  
During further investigations, a better way to sample the release environment should be 
developed. Because the tip of the needle in the modified diffusion cell is close to where the 
beads are located (~2 cm above), the local concentration during sampling may be higher than 
the overall environment, despite attempts to distribute the drug by pumping the syringe prior 
to removing sample. Evidence of this being an issue could be observed during absorbance 
readings, where an unexpected spike in absorbance would be seen early in the sampling 
process. A possible remedy could be inducing agitation during the release period, perhaps 
through addition of magnetic stirring or a shaker plate. 
For future investigation into the usefulness of alginate and PNIPAAm matrices for drug 
release, it is necessary to go beyond investigating the release profile at only body temperature 
and incorporate a study of the release at other body conditions, such as pH. Release studies 
must be conducted in phosphate-buffered saline (PBS) since PBS mimics the body environment 
through providing a pH similar to blood. Also, alginate responds to pH stimulation, and it would 
be important to understand how the incorporation of PNIPAAM influences its behavior in a 
modified pH.  
Further investigations and improvements should be done to confirm and reinforce the 
behavior observed. Many of the discrepancies may be remedied by incorporating additional 
data. One of the biggest improvements to the experimental method that can be made is 
increasing the number of samples taken during the diffusion modeling stage (before 60% 
release is achieved). For example, the 75/25 bead system has only four data points that were 
measured prior to the 60% release point. More data points in this region will increase the 
accuracy of the model, perhaps clarifying some of the cases where the n is near an expected 
case, such as the difference in n values seen between the two alginate controls.  
To increase the accuracy of drug loading measurement, a matrix degradation technique 
should be used to measure the total amount of drug in each bead. Because release profile can 
be influenced by morphology, investigations should be made into techniques that will create a 
uniform bead morphology for every bead solution.  
During observations of the release environment, it was noted that the dry beads often 
released rhodamine immediately upon addition of water. This may be attributed to residual 
rhodamine B being on the surface of the beads. Beads should be rinsed thoroughly prior to 
drying to promote uniform drug loading and prevent spikes in release profile due to initial drug 
loading.  
In conclusion, the addition of PNIPAAm to alginate beads tends to decrease the release 
time, therefore speeding up the drug delivery of the small molecule model drug, rhodamine B, 
into a body-temperature aqueous release environment. Further investigations should include 
the collection of more data to confirm the behavior observed in this experiment. Further 
investigations should also include improvements to the consistency of bead morphology and to 
the release procedure, as well as modeling in PBS as a proof-of-concept for viability as a drug 
release matrix.  
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